ELYXYB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ELYXYB (ELYXYB).
Topical analgesic; inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in peripheral tissues.
| Metabolism | Hepatic via glucuronidation and oxidation; primarily by UGT2B7 and CYP2C9, with minor contributions from CYP3A4 and CYP2C8. |
| Excretion | Primarily renal excretion of metabolites; 70-80% of dose recovered in urine as glucuronide conjugates, with <1% as unchanged drug. Biliary/fecal excretion accounts for approximately 10-20%. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours in healthy adults. No clinically relevant accumulation with repeated dosing at recommended intervals. |
| Protein binding | Approximately 99% bound, primarily to serum albumin. |
| Volume of Distribution | Following topical administration, systemic absorption is minimal; apparent volume of distribution is not clinically meaningful. After intravenous administration in animal studies, Vd is approximately 0.2 L/kg, consistent with distribution into extracellular fluid. |
| Bioavailability | Topical: Absolute bioavailability is less than 1% due to low systemic absorption following application to the skin or scalp. |
| Onset of Action | Topical: Onset of headache relief within 1 hour post-application, as evidenced by pain freedom at 2 hours in clinical trials. |
| Duration of Action | Duration of effect supports single-dose as-needed use for acute migraine; pain relief sustained for up to 24 hours in some patients, but repeat dosing after 2 hours is recommended if needed. |
| Molecular Weight | 343.46 |
Topical application of 5.6 g (one unit dose tube) to the target area of the forehead and temple using the hand-held applicator, applied only once per migraine attack. Maximum dose: 5.6 g per day.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use with caution. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); contraindicated. |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosage. |
| Geriatric use | No dose adjustment required for elderly patients (≥65 years) based on limited data. Use with caution due to potential for increased sensitivity and comorbidities. |
| 1st trimester | No adequate human data; animal studies show no risk at therapeutic doses; use only if benefit outweighs risk. |
| 2nd trimester | No adequate human data; animal studies show no risk at therapeutic doses; use only if benefit outweighs risk. |
| 3rd trimester | Use caution; potential for maternal hypotension and reduced uterine blood flow; avoid near term due to theoretical risk of fetal distress. |
Clinical note
Comprehensive clinical and safety monograph for ELYXYB (ELYXYB).
| Placental transfer | Likely crosses placenta due to low molecular weight; no specific human data; animal studies suggest minimal transfer. |
| Breastfeeding | No human data available; molecular weight suggests potential for excretion; use with caution; monitor infant for sedation or hypotension. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to celecoxib or sulfonamidesHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or NSAIDsPatients with coronary artery bypass graft (CABG) surgery
| Precautions | Risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal; increased risk with longer use or pre-existing cardiovascular disease, Risk of gastrointestinal adverse events including bleeding, ulceration, and perforation, Avoid in setting of coronary artery bypass graft surgery, May cause hypertension, fluid retention, and exacerbation of renal impairment, Anaphylactic reactions may occur, Use with caution in patients with asthma or history of aspirin-sensitive asthma |
| Food/Dietary | No clinically significant food interactions have been reported. Grapefruit juice and other CYP450 inhibitors are unlikely to affect systemic levels due to minimal absorption. Maintain normal diet without restrictions. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | No human data; animal studies insufficient to assess risk. Risk cannot be excluded; use only if benefit outweighs potential fetal risk across all trimesters. |
| Fetal Monitoring | No specific monitoring required beyond standard obstetric care. Monitor for maternal adverse effects; fetal monitoring not specifically indicated. |
| Fertility Effects | No human data on fertility effects. Animal studies have not been conducted to evaluate impact on fertility. |
| Clinical Pearls | ELYXYB (bimatoprost ophthalmic solution) 0.03% is indicated for the treatment of open-angle glaucoma or ocular hypertension. As a prostaglandin analog, it reduces intraocular pressure by increasing uveoscleral outflow. Onset of action occurs within 4 hours, with peak effect at 8-12 hours. Efficacy may be enhanced by concomitant use with other IOP-lowering agents. Monitor for gradual changes in iris pigmentation, eyelash growth, and periorbital tissue effects. Contraindicated in patients with active intraocular inflammation (e.g., uveitis) due to risk of exacerbation. Avoid use in patients with known hypersensitivity to bimatoprost or benzalkonium chloride. Systemic absorption is minimal but caution in patients with compromised respiratory function (e.g., asthma) due to rare bronchospasm reports. |
| Patient Advice | Wash hands before and after instillation to avoid contamination. · Remove contact lenses before administration and wait at least 15 minutes before reinsertion, as benzalkonium chloride may be absorbed by soft lenses. · Apply one drop in the affected eye(s) once daily in the evening; use exactly as prescribed, do not skip doses. · Do not touch the dropper tip to any surface, including the eye, to prevent infection. · If using other topical ophthalmic medications, separate administration by at least 5 minutes to prevent washout. · May cause temporary blurred vision; avoid driving or operating machinery until vision clears. · Report any signs of eye inflammation, eye pain, or vision changes immediately. · Inform healthcare provider if pregnant, planning to become pregnant, or breastfeeding, as safety has not been established. · Iris color may permanently darken; eyelashes may become longer, thicker, and darker, or additional eyelashes may grow. · Do not use if the solution changes color or becomes cloudy; store at room temperature away from light. |